<DOC>
	<DOC>NCT01773122</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Diagnosis of acne vulgaris Willing to avoid excessive or prolonged exposure to ultraviolet light (e.g., sunlight, tanning beds) throughout the study If male, the subject must agree to shave the facial treatment area and agree to maintain his routine shaving regimen for the duration of the study willing to avoid applying moisturizers, sunscreens, cosmetics (except eye and lip makeup), and chemical peels throughout the study Oral acne treatments within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>